{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:21:57Z","timestamp":1789543317704,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.annder.2013.10.054","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T18:00:16Z","timestamp":1387044016000},"page":"215-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["N\u00e9crolyse \u00e9pidermique toxique au vemurafenib"],"prefix":"10.1016","volume":"141","author":[{"given":"M.","family":"Wantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Spanoudi-Kitrimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-F.","family":"Quinchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Modiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2013.10.054_bib0005","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.10.054_bib0010","first-page":"111","article-title":"Imputabilit\u00e9 des effets inattendus ou toxiques des m\u00e9dicaments. Actualisation de la m\u00e9thode utilis\u00e9e en France","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"key":"10.1016\/j.annder.2013.10.054_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"8","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2013.10.054_bib0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"67","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.10.054_bib0025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/CMR.0b013e3283573437","article-title":"Succesful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib","volume":"22","author":"Minor","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2013.10.054_bib0030","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.10.054_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D38W90X9ZB","article-title":"A case of vemurafenib-induced keratosis pilaris-like eruption","volume":"18","author":"Wang","year":"2012","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2013.10.054_bib0040","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.jaad.2012.06.043","article-title":"Keratosis pilaris-like eruption observed during the experimental PLX 4032\u00a0studies","volume":"67","author":"Van der Kooi","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.10.054_bib0045","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42\u00a0patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2013.10.054_bib0050","first-page":"7","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"18","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.10.054_bib0055","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.10.054_bib0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2013.10.054_bib0065","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.10.054_bib0070","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.jaad.2012.05.019","article-title":"Vasculitis and panniculitis associated with vemurafenib","volume":"67","author":"Novoa","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.10.054_bib0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.10.054_bib0080","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archdermatol.2012.758","article-title":"Unusal complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by kaposi varicelliform eruption","volume":"148","author":"Gupta","year":"2012","journal-title":"Arch Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813017456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813017456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:01:41Z","timestamp":1758970901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963813017456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0151963813017456"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2013.10.054","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9crolyse \u00e9pidermique toxique au vemurafenib","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2013.10.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}